Targeting the ear (specifically the inner ear/cochlea) with AAV is a rapidly advancing field, primarily focused on treating sensorineural hearing loss and vestibular (balance) disorders. The primary challenge is the Blood-Labyrinth Barrier and the delicate, hard-to-reach anatomy of the cochlea.

Quick Legend: Administration Routes

• RWM (Round Window Membrane): A semi-permeable membrane at the base of the cochlea. Injection into or through this membrane is a common, relatively safe clinical route.
• Cochleostomy: A surgical opening made directly into the bony wall of the cochlea (typically the scala media). Offers direct access but carries a higher risk of damaging the delicate endocochlear potential.
• Canalostomy: Injection through a semicircular canal (often the posterior canal). This route allows the vector to flow through the vestibular system and into the cochlea, often providing broad coverage with less risk to hearing.

---

1. Natural AAV Serotypes

Serotype	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV1	Inner Hair Cells (IHCs)	RWM / Canal	The IHC Specialist. • One of the most efficient natural serotypes for targeting the primary sensory cells (IHCs). • Often used in “proof-of-concept” hearing restoration studies for diseases like DFNB9 (Otoferlin).
AAV2	Inner Hair Cells, Supporting Cells	RWM	Standard Reference. • Transduces IHCs well but generally fails to reach Outer Hair Cells (OHCs), which are critical for sound amplification.
AAV9	IHCs, Spiral Ganglion Neurons (SGNs)	RWM / Canal	Broad Distribution. • Known for its ability to penetrate deeper into the auditory nerve and spiral ganglion compared to AAV2.
AAV8	IHCs, Supporting Cells	RWM	Similar to AAV1/2; highly effective in neonatal models but efficiency drops significantly in mature, adult ears.
AAV5	Supporting Cells (SCs)	Cochleostomy	Shows a unique preference for non-sensory supporting cells, which are targets for regeneration studies (converting SCs into new hair cells).

---

2. Engineered & Synthetic Capsids

Natural AAVs struggle to transduce Outer Hair Cells (OHCs), which is essential for restoring high-sensitivity hearing. Engineered capsids solve this “OHC gap.”

Variant	Primary Target Cells	Preferred Route	Key Characteristics & Notes
Anc80L65	IHCs & OHCs (100% efficiency)	RWM / Canal	The Industry Gold Standard. • A synthetic ancestral capsid that “unlocked” the outer hair cells. • Achieves nearly 100% transduction across the entire cochlea, making it the top choice for complex hearing disorders.
AAV-PHP.B	IHCs, OHCs, & Vestibular Cells	RWM / Canal	Originally a CNS vector (AAV9 variant). • Highly potent in both mice and non-human primates (NHPs). • Transduces nearly all cell types in the Organ of Corti.
AAV-S	IHCs, OHCs, Fibrocytes	RWM / Canal	Primate-Optimized. • An engineered capsid specifically validated for robust transduction in both rodents and monkeys. • Successfully used to rescue hearing in models of Usher Syndrome.
Exo-AAV	All Hair Cells	RWM	Exosome-Enveloped. • AAV vectors “wrapped” in exosomes. This biological shielding significantly improves penetration into hair cells and protects the virus from the immune system.

---

3. Tropism by Target Cell

If you are targeting a specific cell population in the ear:

• Inner Hair Cells (IHCs): Most serotypes work (AAV1, AAV2, AAV9, Anc80).
• Outer Hair Cells (OHCs): Use Anc80L65, AAV-S, or AAV-PHP.B. Natural serotypes will fail here.
• Spiral Ganglion Neurons (Auditory Nerve): AAV9 or AAV-PHP.B.
• Supporting Cells (for Regeneration): AAV5 or AAV-Anc80.
• Vestibular System (Balance): AAV-S or AAV1 via semicircular canal injection.

Critical Factor: Neonatal vs. Adult Ears

In hearing research, timing is everything:

1. The Neonatal Window: In mice, the ear is still developing after birth. Most AAVs work incredibly well during the first 3 days (P0-P3).
2. The Adult Barrier: In mature ears (and humans), the structures are “hardened.” Many natural serotypes that work in babies fail in adults. This is why engineered capsids like Anc80 or AAV-S are required for clinical-stage human therapies.